Obesity management for cardiovascular disease prevention

[1]  K. Hod,et al.  Long-term Reported Outcomes Following Primary Laparoscopic Sleeve Gastrectomy , 2022, Obesity Surgery.

[2]  H. Bays.  What about that 2022 ICER report on anti-obesity medications? , 2022, Obesity Pillars.

[3]  J. Pratt,et al.  2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. , 2022, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[4]  L. Aronne,et al.  Tirzepatide Once Weekly for the Treatment of Obesity. , 2022, The New England journal of medicine.

[5]  H. Bays,et al.  Obesity pillars roundtable: Phentermine – Past, present, and future , 2022, Obesity Pillars.

[6]  H. Bays,et al.  Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 , 2022, Obesity Pillars.

[7]  M. Raffaelli,et al.  Single anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S): experience from a high-bariatric volume center , 2022, Langenbeck's Archives of Surgery.

[8]  R. Seeley,et al.  Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide , 2021, JCI insight.

[9]  H. Heerspink,et al.  SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications , 2021, The Lancet.

[10]  J. Rosenstock,et al.  Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. , 2021, The New England journal of medicine.

[11]  S. Purkayastha,et al.  LONG-TERM CARDIOVASCULAR OUTCOMES AFTER ORLISTAT THERAPY IN PATIENTS WITH OBESITY: A NATIONWIDE, PROPENSITY SCORE MATCHED COHORT STUDY , 2021 .

[12]  C. Aguilar-Salinas,et al.  Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta‐analyses , 2021, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[13]  M. Murad,et al.  AGA Clinical Practice Guidelines on Intragastric Balloons in the Management of Obesity. , 2021, Gastroenterology.

[14]  M. Sorribas,et al.  Experience in biliopancreatic diversion with duodenal switch: results at 2, 5 and 10 years. , 2021, Cirugia espanola.

[15]  T. Wadden,et al.  Once-Weekly Semaglutide in Adults with Overweight or Obesity. , 2021, The New England journal of medicine.

[16]  G. Hovingh,et al.  Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. , 2020, American heart journal.

[17]  A. Rogers,et al.  American Society for Metabolic and Bariatric Surgery updated statement on single-anastomosis duodenal switch. , 2020, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[18]  R. Cervelli,et al.  Laparoscopic adjustable gastric banding, the past, the present and the future , 2020, Annals of translational medicine.

[19]  C. Thompson,et al.  Effect of Aspiration Therapy on Obesity-Related Comorbidities: Systematic Review and Meta-Analysis , 2020, Clinical endoscopy.

[20]  L. Fischer,et al.  Learning Curves of Laparoscopic Roux-en-Y Gastric Bypass and Sleeve Gastrectomy in Bariatric Surgery: a Systematic Review and Introduction of a Standardization , 2020, Obesity surgery.

[21]  S. Y. Lee,et al.  Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review , 2020, The world journal of men's health.

[22]  J. J. Gorgojo-Martínez,et al.  Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real‐world setting: The XENSOR Study , 2019, International journal of clinical practice.

[23]  J. McMurray,et al.  Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. , 2019, The lancet. Diabetes & endocrinology.

[24]  T. Vilsbøll,et al.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2019, The New England journal of medicine.

[25]  Muhammad Zeeshan,et al.  New Era: Endoscopic treatment options in obesity–a paradigm shift , 2019, World journal of gastroenterology.

[26]  Jay R. Desai,et al.  Safety and Effectiveness of Longer‐Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort , 2019, Obesity.

[27]  S. Skinner,et al.  Long-Term Outcomes After Bariatric Surgery: a Systematic Review and Meta-analysis of Weight Loss at 10 or More Years for All Bariatric Procedures and a Single-Centre Review of 20-Year Outcomes After Adjustable Gastric Banding , 2018, Obesity Surgery.

[28]  P. Kowey,et al.  Cardiovascular Safety During and After Use of Phentermine and Topiramate , 2018, The Journal of clinical endocrinology and metabolism.

[29]  D. Magouliotis,et al.  Impact of Laparoscopic Sleeve Gastrectomy on Gastrointestinal Motility , 2018, Gastroenterology research and practice.

[30]  A. Juuti,et al.  Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial , 2018, JAMA.

[31]  C. Voils,et al.  Bariatric surgery barriers: a review using Andersen's Model of Health Services Use. , 2017, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[32]  S. Hunt,et al.  Weight and Metabolic Outcomes 12 Years after Gastric Bypass , 2017, The New England journal of medicine.

[33]  Amit P. Desai,et al.  Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[34]  C. Thompson,et al.  Clinical Practice Update: Expert Review on Endoscopic Bariatric Therapies. , 2017, Gastroenterology.

[35]  N. Nguyen,et al.  Roux-en-Y Gastric Bypass , 2005 .

[36]  A. Mehta,et al.  Liraglutide for weight management: a critical review of the evidence , 2016, Obesity science & practice.

[37]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[38]  M. Camilleri,et al.  Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. , 2016, JAMA.

[39]  B. Wolfe,et al.  Treatment of Obesity: Weight Loss and Bariatric Surgery. , 2016, Circulation research.

[40]  L. Aronne,et al.  Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial , 2016, International Journal of Obesity.

[41]  B. Capaldo,et al.  Effects of bariatric surgery on markers of subclinical atherosclerosis and endothelial function: a meta-analysis of literature studies , 2016, International Journal of Obesity.

[42]  J. Rey,et al.  Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults. , 2016, P & T : a peer-reviewed journal for formulary management.

[43]  C. Apovian.  Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. , 2016, Future cardiology.

[44]  J. Dixon,et al.  LAP-BAND for BMI 30–40: 5-year health outcomes from the multicenter pivotal study , 2016, International Journal of Obesity.

[45]  F. Rubino,et al.  Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial , 2015, The Lancet.

[46]  C. Thompson,et al.  ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. , 2015, Gastrointestinal endoscopy.

[47]  C. Apovian,et al.  Sustained Weight Loss with Vagal Nerve Blockade but Not with Sham: 18-Month Results of the ReCharge Trial , 2015, Journal of obesity.

[48]  A. Astrup,et al.  A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. , 2015, The New England journal of medicine.

[49]  C. Ricci,et al.  Long-Term Effects of Bariatric Surgery on Type II Diabetes, Hypertension and Hyperlipidemia: A Meta-Analysis and Meta-Regression Study with 5-Year Follow-Up , 2015, Obesity Surgery.

[50]  L. Aronne,et al.  Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study , 2014, International Journal of Obesity.

[51]  James Toouli,et al.  Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. , 2014, JAMA.

[52]  A. Astrup,et al.  Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity , 2014, Journal of hypertension.

[53]  S. Anderson,et al.  Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. , 2014, International journal of cardiology.

[54]  Luis Garcia,et al.  Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. , 2013, JAMA.

[55]  F. Greenway,et al.  Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes , 2013, Diabetes Care.

[56]  S. Oparil,et al.  Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2). , 2013, The American journal of cardiology.

[57]  P. Schauer,et al.  Bariatric surgery and cardiovascular outcomes: a systematic review , 2012, Heart.

[58]  M. Marcus,et al.  Psychopathology before surgery in the longitudinal assessment of bariatric surgery-3 (LABS-3) psychosocial study. , 2012, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[59]  C. Bouchard,et al.  Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. , 2012, The New England journal of medicine.

[60]  M. Myers,et al.  Role of GABA release from leptin receptor-expressing neurons in body weight regulation. , 2012, Endocrinology.

[61]  K. Gadde,et al.  Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2011, The American journal of clinical nutrition.

[62]  F. Greenway,et al.  Blood Pressure and Heart Rate Effects, Weight Loss and Maintenance During Long‐Term Phentermine Pharmacotherapy for Obesity , 2011, Obesity.

[63]  K. Gadde,et al.  Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) , 2011, Obesity.

[64]  Daniel B. Jones,et al.  First Report from the American College of Surgeons Bariatric Surgery Center Network: Laparoscopic Sleeve Gastrectomy has Morbidity and Effectiveness Positioned Between the Band and the Bypass , 2011, Annals of surgery.

[65]  A. Astrup,et al.  Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide , 2011, International Journal of Obesity.

[66]  Benjamin Chavez,et al.  Naltrexone SR/Bupropion SR (Contrave): A New Approach to Weight Loss in Obese Adults. , 2011, P & T : a peer-reviewed journal for formulary management.

[67]  C. Rock,et al.  Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial , 2011, Obesity.

[68]  F. Greenway,et al.  Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2010, The Lancet.

[69]  A. Astrup,et al.  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.

[70]  B. Wolfe,et al.  Perioperative safety in the longitudinal assessment of bariatric surgery. , 2009, The New England journal of medicine.

[71]  C. Fernández,et al.  Proximal Duodenal–Ileal End-to-Side Bypass with Sleeve Gastrectomy: Proposed Technique , 2007, Obesity surgery.

[72]  Claude Bouchard,et al.  Effects of bariatric surgery on mortality in Swedish obese subjects. , 2007, The New England journal of medicine.

[73]  Claude Bouchard,et al.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. , 2004, The New England journal of medicine.

[74]  Alessandro Pontillo,et al.  Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. , 2003, JAMA.

[75]  K. Flegal,et al.  Criteria for definition of overweight in transition: background and recommendations for the United States. , 2000, The American journal of clinical nutrition.

[76]  A. Heck,et al.  Orlistat, a New Lipase Inhibitor for the Management of Obesity , 2000, Pharmacotherapy.

[77]  S. Rössner,et al.  Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. , 1999, International Journal of Obesity.

[78]  S. Rössner,et al.  Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. , 1998, The American journal of clinical nutrition.

[79]  OUP accepted manuscript , 2022, European Heart Journal.

[80]  ReShape and Orbera--two gastric balloon devices for weight loss. , 2015, The Medical letter on drugs and therapeutics.

[81]  M. Mattson,et al.  GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. , 2011, Cardiovascular research.